Health Care
Commentary
Business Policy CMS Shouldn’t Expand Its Broken Competitive Bidding Model
Durable medical equipment (DME) such as CPAP machines and hospital beds helps keep many patients out of expensive nursing home care and in their own homes. Unfortunately, creating the right payment model has long eluded the Centers for Medicare and Medicaid Services (CMS). Disconcertingly, they now plan to expand a ...
Commentary
Trump’s Medicaid reform is moral and necessary
Among the most contentious provisions in the One Big Beautiful Bill Act, which President Donald Trump signed into law on July 4, are its Medicaid work requirements. Starting in 2027, able-bodied, working-age Medicaid beneficiaries enrolled through Obamacare’s expansion of the program must spend at least 80 hours a month on ...
Commentary
Thanks to Obamacare, Insurance Fraud Irresistible
Something strange is afoot on the Obamacare exchanges. According to a new study by the Paragon Health Institute, an astounding number of patients with premium-free exchange plans filed no claims whatsoever last year. It’s possible that none of these individuals required medical care in 2024. Read the op-ed here.
Commentary
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Commentary
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Commentary
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Commentary
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary
The rural hospital rescue fund is a fraud
Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Business Policy CMS Shouldn’t Expand Its Broken Competitive Bidding Model
Durable medical equipment (DME) such as CPAP machines and hospital beds helps keep many patients out of expensive nursing home care and in their own homes. Unfortunately, creating the right payment model has long eluded the Centers for Medicare and Medicaid Services (CMS). Disconcertingly, they now plan to expand a ...
Trump’s Medicaid reform is moral and necessary
Among the most contentious provisions in the One Big Beautiful Bill Act, which President Donald Trump signed into law on July 4, are its Medicaid work requirements. Starting in 2027, able-bodied, working-age Medicaid beneficiaries enrolled through Obamacare’s expansion of the program must spend at least 80 hours a month on ...
Thanks to Obamacare, Insurance Fraud Irresistible
Something strange is afoot on the Obamacare exchanges. According to a new study by the Paragon Health Institute, an astounding number of patients with premium-free exchange plans filed no claims whatsoever last year. It’s possible that none of these individuals required medical care in 2024. Read the op-ed here.
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
The rural hospital rescue fund is a fraud
Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
